

1 **Metabolic alterations in human post-mortem frontal cortex and cerebrospinal fluid**
2 **associated with high levels of nicotine metabolite cotinine.**

3 Wadzanai Masvosva¹, Marko Lehtonen¹, Mika Martiskainen^{2,3}, Jari Tiihonen^{4,5}, Pekka J.

4 Karhunen², Kati Hanhineva^{6,7}, Jaana Rysä¹, Eloise Kok², and Olli Kärkkäinen¹. *

5 ¹ School of Pharmacy, University of Eastern Finland, Finland

6 ² Faculty of Medicine and Health Technology, Tampere University, Finland and Fimlab

7 Laboratories Ltd, Tampere University Hospital Region, Finland

8 ³ Finnish Institute for Health and Welfare, Finland

9 ⁴ Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital,
10 Finland

11 ⁵ Department of Clinical Neuroscience, Karolinska Institutet and Center for Psychiatry
12 Research, Stockholm City Council, Stockholm, Sweden

13 ⁶ Department of Life Technologies, Food sciences unit, University of Turku, Finland

14 ⁷ School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern
15 Finland, Finland

16

17 * Correspondence: Olli Kärkkäinen, olli.karkkainen@uef.fi, School of Pharmacy, University
18 of Eastern Finland, 70210 Kuopio, Finland

19

20 **Ethics approval statement**

21 The Tampere Sudden Death Study (TSDS) protocol was approved by the Ethics Committee
22 of Pirkanmaa Hospital District (Permission number R09097) and the National Supervisory
23 Authority for Welfare and Health Valvira (Dnro 564/05.01.00.06/2010). This was in
24 accordance with the Declaration of Helsinki.

25 **Data availability**

26 The data that support the findings of this study are available on request from the
27 corresponding author, OK. The study plan approved by the ethical committee and the
28 participant consent terms preclude public sharing of these sensitive data, even in
29 anonymized form.

30 **Funding statement**

31 This study is funded by the Finnish Foundation for Alcohol Studies (OK), VTR funding (JT,
32 PJK), European Union 7th Framework Program grant number 201668 for AtheroRemo
33 Project (PJK), by State Research Funding for Tampere University Hospital (PJK), Pirkanmaa
34 Regional Fund of the Finnish Cultural Foundation (PJK), Finnish Cultural Foundation (EK),
35 Jane and Aatos Erkko Foundation (PJK, KH), Research Council of Finland (KH), and the
36 Finnish Foundation for Cardiovascular Research (PJK).

37 **Conflict of Interest**

38 OK and KH are founders of Afekta Technologies Ltd., a company offering metabolomics
39 analysis services. Other authors report no potential conflicts of interest.

40 **Acknowledgements**

41 We thank Miia Reponen for the excellent technical assistance with the mass spectrometry
42 analyses. The authors want to thank Biocenter Finland and Biocenter Kuopio for
43 supporting their core LC-MS laboratory facility.

44 **Abstract**

45 Cigarette smoking is the single most significant cause of preventable death in the world.
46 Tobacco smoking causes exposure to thousands of chemicals and disrupts biological
47 pathways. It impacts several organs, including the brain, where its effects are mediated by
48 nicotinic acetylcholine receptors. Women seem to be more susceptible to the negative
49 health effects of smoking. In this study we focused on the changes in the metabolic profile
50 of human postmortem frontal cortex and cerebrospinal fluid samples associated with high
51 levels of the nicotine metabolite cotinine. We used non-targeted metabolomics to analyze
52 post-mortem frontal cortex and cerebrospinal fluid (CSF) samples from the Tampere
53 Sudden Death Study cohort. We identified 137 cases (24 females) with high cotinine levels,
54 indicating nicotine exposure. For controls, we identified 82 subjects (20 females) with no
55 cotinine in the frontal cortex or CSF samples and no known history of smoking based on
56 medical records and autopsy reports. Cases had significantly higher levels of 1-
57 methylhistamine (Cohen's $d=0.66$, $p<0.0001$) and N-acetylputrescine ($d=0.84$, $p<0.0001$),
58 and lower levels of aspartic acid ($d=-0.53$, $p<0.001$), 3-methylhistidine ($d=-0.58$, $p=0.0004$),
59 and taurine ($d=-0.47$, $p=0.0002$) in the frontal cortex compared to controls. Compared to
60 the frontal cortex, differences between cases and controls were smaller in the CSF samples.
61 Most of the observed differences were similar in both sexes, with a few exceptions like low
62 ergothioneine levels, observed especially in female cases. In conclusion, smoking or
63 nicotine exposure is associated with alterations in metabolites linked to increased oxidative

64 stress and neuroinflammation, as well as reduced neurotransmitter levels in the frontal

65 cortex.

66 Key words: tobacco, nicotine, smoking, metabolite profile.

67 **Introduction**

68 Cigarette smoking is the single most significant cause of preventable death in the world¹.

69 Tobacco smoking causes exposure to thousands of chemicals and can disrupt several

70 biological pathways, leading to negative health effects. A key component in tobacco is

71 nicotine, which is considered to be the main cause of addiction to tobacco smoking and is

72 currently also used in e-cigarettes, nicotine replacement products, and other tobacco-free

73 nicotine products². For example, nicotine is an important factor in the initiation and

74 progression of smoking-induced atherosclerosis³. Nicotine also dysregulates apoptosis

75 signaling pathways, which in turn initiates lung cell apoptosis and contributes to lung

76 diseases⁴. In human metabolism, nicotine is converted to cotinine that can be used to

77 assess recent nicotine exposure⁵.

78 Besides the heart and lungs, the brain is a target organ for nicotine, where its effects are

79 mediated by nicotinic acetylcholine receptors⁶. Repeated long-term exposure to nicotine

80 alters the function of the brain. For example, it increases the levels of nicotinic

81 acetylcholine receptors, which in turn affects other neurotransmitter systems, including

82 glutamatergic and GABAergic systems⁷. Neuroimaging and neuropathological

83 investigations show a wide range of effects of nicotine exposure on the brain. Nicotine

84 exposure has also been associated with damage to the endothelial cells, resulting in an

85 increased risk of cerebrovascular disease⁸. Smoking has been connected to structural

86 decreases in brain regions such as the right cerebellum, multiple prefrontal cortex regions

87 and the thalamus. This decrease in gray matter seems to have structural-behavioral
88 implications, such as visual processing problems in the prefrontal cortex⁹.
89 Moreover, some of the effects of nicotine on the brain seem to differ between sexes¹⁰. For
90 example, when exposed to tobacco smoking, males show reduced left caudate volume with
91 altered functional connectivity, whereas females show a decreased right amygdala volume
92 and altered impulsivity correlations¹¹. However, possible sex differences in the metabolic
93 pathways of human brain are not known.

94 Non-targeted metabolomics is an excellent tool for measuring the effects of complex
95 chemical exposures, such as tobacco smoking. Non-targeted metabolomics measures
96 hundreds of endogenous, microbiota associated, and exogenous small molecules in a
97 sample and can therefore provide wide understanding of metabolic adaptations related to
98 different exposures¹². Smoking is associated with alterations in the circulating metabolite
99 profile¹³⁻¹⁷. Some of these changes could be important for brain function and may be
100 associated with nicotine dependence. For example, both tobacco smoking and use of
101 heated tobacco products have been linked with high blood levels of glutamate, the main
102 excitatory neurotransmitter^{14,16}. On the other hand, reduced blood levels of glutamate
103 seem to be an acute effect of cigarette smoking in current smokers¹⁵. Furthermore, levels
104 of another neurotransmitter, serotonin, has been reported to be increased in the blood in
105 current smokers¹³. However, circulating levels might not reflect levels in the brain¹⁸.
106 Understanding how tobacco smoking or nicotine exposure alters the brain metabolome
107 could be important for understanding brain related pathology associated with tobacco,

108 including nicotine dependence. However, no metabolomics studies have been performed
109 to investigate the effects of tobacco smoking or nicotine exposure on human brain tissue.
110 Here, our aim was to investigate changes in the human brain and cerebrospinal fluid (CSF)
111 metabolite profiles associated with tobacco smoking or nicotine exposure. We conducted a
112 non-targeted metabolomics analysis using post-mortem frontal cortex and CSF samples to
113 gain novel insights into tobacco smoking or nicotine exposure-related changes in the
114 metabolic processes of the human brain. We also investigated possible sex-dependent
115 associations in the post-mortem samples.

116 **Methods and Materials**

117 *Subjects*

118 We used post-mortem frontal cortex and CSF samples from the Tampere Sudden Death
119 Study (TSDS) cohort¹⁹. The samples were collected from forensic autopsies on people who
120 suffered out-of-hospital deaths in the area of the Pirkanmaa Hospital District (Finland)
121 during 2010-2015. Frontal cortex (Brodmann area 9) and CSF samples, a portion extracted
122 via syringe, were collected from a total of 700 subjects and stored at -80 °C until use.

123 The inclusion criteria for the current study cases were high cotinine (metabolite of nicotine)
124 levels in the CSF and frontal cortex samples. Smoking status, based on medical and
125 autopsy records, was missing from 64 cases (47%). Of those with a known smoking history,
126 most were tobacco smokers (69, 95%) and the rest smoked pipes or cigars. No cotinine in
127 the samples and no known history of smoking were inclusion criteria for the control group.
128 We excluded seven subjects who did not show smoking in medical records, but did have
129 high cotinine levels in frontal cortex or CSF samples. Furthermore, we excluded one subject
130 who was classified as a smoker based on medical records, but did not have any cotinine in
131 the frontal cortex or CSF samples. In the end, we had 137 subjects in the smoking group
132 and 82 in the control group (Table 1).

133 **Table 1:** Background characteristics

Variable	Controls (n=82)	Cases (n=137)	p-value
Age (years; mean±SD)	57 ± 14	53 ± 14	0.0627 ^a
Sex (Females, n (%))	20 (24%)	24 (18%)	0.2193 ^b
BMI (mean±SD)	30.4±6.8	28.5 ± 7.8	0.0548 ^a
PMI (days, mean±SD)	5.8 ± 2.5	5.3 ± 2.4	0.1592 ^a
Brain (grams, mean±SD)	1490 ± 139	1459 ± 151	0.1257 ^a
Cause of death (n (%))			0.4202 ^b
Accident	5 (6.1%)	4 (2.9%)	
Alcohol/drug poisoning	6 (7.3%)	20 (14.6%)	
Alcohol-related disease	7 (8.5%)	14 (10.2%)	
Cardiovascular disease	40 (48.8%)	50 (36.5%)	
Diabetes	3 (3.7%)	5 (3.6%)	
Suicide	10 (12.2%)	21 (15.3%)	
Other	10 (12.2%)	18 (13.1%)	
Unknown	1 (1.2%)	5 (3.6%)	

134 Table legend: ^a, Welch's t-test; ^b, χ^2 test; BMI, body mass index; PMI, post-mortem interval.
135

136 *Non-targeted metabolomics analysis*

137 The LC-MS analysis of the frontal cortex and CSF samples has been described in detail by
138 Kärkkäinen et al (2021)¹⁹. In brief, tissue samples were weighed with an added 80%
139 methanol (v/vH₂O, LC-MS Ultra CHROMASOLV®, Fluka). 1000 μ L solvent was added for
140 each 100 mg of frontal cortex tissue. For the CSF samples, 400 μ L of acetonitrile (VWR
141 International, LC-MS grade) was added to 100 μ L of CSF and mixed by pipette. Quality
142 control samples were made by taking 5 μ L solution of each sample. The samples were
143 analyzed using a UHPLC-qTOF-MS system (Agilent Technologies, Waldbronn, Karlsruhe,
144 Germany). It consisted of a 1290 LC system, a jet stream electrospray ionization (ESI) source
145 and 6540 UHD accurate mass qTOF spectrometer. Samples were analyzed using two
146 chromatographic techniques, reversed-phase (RP, Zorbax Eclipse XDB-C18, particle size 1.8

147 μm , dimensions of 2.1×100 mm, Agilent Technologies, USA) and hydrophilic interaction
148 (HILIC, Acquity UPLC BEH Amide $1.7 \mu\text{m}$, 2.1×100 mm, Waters, Ireland), with both positive
149 and negative ionization. Quality control samples were injected at the beginning of the
150 analysis and at every 12th sample. The analysis order of the samples was randomized.
151 Three different collision-induced dissociation voltages were used (10, 20, and 40 eV) for the
152 data-dependent tandem mass spectrometry (MSMS) analysis.

153 Metabolomics data-analysis was performed using MS-DIAL ver. 3.40²⁰ and Notame R-
154 package²¹. The peak picking and peak alignment parameters were: 1) mass range from 40
155 to 1000 (HILIC) or 1600 (RP) Da, MS tolerance 0.005 Da, MS2 tolerance 0.01 Da, minimum
156 peak width 10 scans, minimum peak height 10,000 (selected based on background noise
157 level). Peaks needed to be detected in at least 70% of samples from one study group to be
158 included in the final data matrix. Drift correction of the metabolomics data was done using
159 results from the QC sample, according to a previously published protocol²¹. In brief, the
160 molecular features were corrected for the drift pattern caused by the LC-MS procedures
161 using regularized cubic spline regression, fit separately for each feature on the QC samples.
162 The smoothing parameter was chosen from an interval between 0.5 and 1.5 using leave-
163 one-out cross-validation to prevent overfitting. After the drift correction, feature quality
164 was assessed, and low-quality features were flagged. Features were kept if their RSD* was
165 below 20% and their D-ratio below 40%. In addition, features with classic RSD, RSD*, and
166 basic D-ratio all below 10% were kept. This additional condition prevents the flagging of
167 features with very low values in all but a few samples. Missing values were imputed using

168 random forest imputation. QC samples were removed prior to imputation to prevent them
169 from affecting the imputation.

170 Metabolite identification was focused on statistically significantly altered (see “statistical
171 analysis”) molecular features. Metabolite identification was based on exact mass, isotopic
172 pattern, MS/MS fragmentation and retention time. Identifications were ranked according to
173 community guidelines²². Metabolites at level 1 were matched to an in-house library built
174 with chemical standards using the same experimental conditions. Level 2 includes
175 metabolites matching the exact mass and MSMS spectra from public libraries (METLIN,
176 LipidMaps, and Human Metabolome Database were used) or, in the case of lipids, the built-
177 in MS-DIAL library version 3.40. In level 3, only the chemical group of the compound (but
178 not the exact compound) is identifiable. Level 4 indicates unidentified compounds.

179 *Statistical analysis*

180 We used Welch’s t-test (continuous variables) and χ^2 test (binomial variables) to evaluate
181 differences between the study groups in background characteristics. We used Welch’s t-test
182 and Cohen’s d-effect sizes to evaluate differences between the study groups in the
183 metabolomics data. To estimate the possible role of sex, we performed additional analysis
184 separately for both sexes. To account for multiple testing, we adjusted the α level by the
185 number of principal components needed to explain 95% of the variation in the data. Here,
186 133 principal components were needed, and therefore the α level was adjusted to 0.0004.
187 P-values between 0.05 and 0.0004 were considered trends. For multivariate analysis, we


188 used partial least squares discriminant (PLS-DA) analysis using SIMCA (v 17.0, Sartorius
189 Stedim Data Analytics Solutions) to calculate variable importance to projection (VIP) values.
190 Identified metabolites with p-value < 0.05 were correlated with PMI using Pearson's
191 method.

192 **Results**

193 The background characteristics (age, sex distribution, body mass index [BMI], post-mortem
194 interval [PMI], brain weight and causes of death) were similar between the study groups.


195 The cases in comparison to the controls, tended to be younger and slightly less overweight,
196 however, these differences did not reach statistical significance (Table 1).

197 In the metabolomics analysis, both frontal cortex and CSF samples showed differences
198 between the study groups in metabolite profiles (Figures 1-3, Supplementary Table S1). As
199 per the selection criteria, the nicotine metabolite cotinine was significantly higher in both
200 frontal cortex and CSF samples in the cases. In the frontal cortex, there were also higher
201 levels of N-acetylputrescine (Cohen's $d = 0.84$, $p < 0.0001$) and 1-methylhistamine ($d = 0.66$,
202 $p < 0.0001$), and lower levels of aspartic acid ($d = -0.53$, $p = 0.0002$) and 3-methylhistidine (d
203 $= -0.58$, $p = 0.0004$) in the cases compared to controls, which were statistically significant
204 after adjusting the α level for multiple testing. In the CSF samples, only the cotinine
205 difference between the study groups was significant at the multiple testing-corrected α
206 level (0.0004). Furthermore, there were several other metabolites (e.g., amino acids,
207 xanthines and B-vitamins), which were lower in abundance in the cases as compared to the
208 controls in the frontal cortex (Figure 2) and CSF samples (Figure 3), with p-values between
209 0.05 and 0.0004. These findings should be considered trends.




210

211 **Figure 1:** The volcano plots show differences in the frontal cortex and CSF metabolite
212 profile between cases and controls. P-values (Welch's t-test), Cohen's d effect sizes and
213 variable importance for projection (VIP, from multivariate PLS-DA analysis) values of all
214 seen molecular features in post-mortem frontal cortex samples are shown in **Fig. 1A**, and
215 all molecular features in the cerebrospinal fluid samples are shown in **Fig. 1B**. Some
216 highlighted features were significantly altered between samples of the study groups
217 (multiple testing adjusted α level = 0.0004, Bonferroni's correction).



219 **Figure 2:** Differences between the study groups in the frontal cortex metabolome.
220 Individual values and group means \pm 95% confidence intervals are shown. P-values from
221 Welch's t-test comparison between all cases and controls is shown as a number. P-values
222 below 0.0004 are significant after correction for multiple testing and p-values between 0.05
223 and 0.0004 should be considered trends. Welch's t-test comparisons between same sex
224 cases and controls (male cases vs. male controls, female cases vs. female controls) are
225 shown with asterisks: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$. (Gray: control vs purple: case)

226



227

228 **Figure 3:** High cotinine levels are associated with alterations in the cerebrospinal fluid
 229 metabolome. Individual values and group means \pm 95% confidence intervals are shown. P-
 230 values from Welch's t-test below 0.0004 are significant after correction for multiple testing
 231 and p-values between 0.05 and 0.0004 should be considered trends. Welch's t-test

232 comparisons between same sex cases and controls (male cases vs. male controls, female
233 cases vs. female controls) are shown with asterisks: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.
234 (Gray: control vs purple: case)

235

236 To estimate possible differences between sexes, we performed the statistical analysis
237 separately for both sexes. For all key findings, the direction of the difference in metabolite
238 levels between cases and controls remained the same (Supplementary Table S1). For most
239 of the key findings, the Cohen's d effect size also remained at relatively similar levels,
240 although some metabolites did show a more pronounced difference between female cases
241 and controls (e.g., lower levels of ergothioneine, $d = -1.06$, and glutamate, $d = -1.08$, in the
242 frontal cortex, and higher levels of leucic acid, $d = 0.72$, and glutamine, $d = 0.69$, in the CSF,
243 Supplementary Table S1). However, due to reduced statistical power, most p-values were $>$
244 0.05 in the comparison between the study groups when analyzing data only from female
245 subjects.

246 Correlation analysis showed that in the frontal cortex, PMI was positively associated with
247 aspartic acid ($r = 0.225$, $p < 0.001$), asparagine ($r = 0.389$, $p < 0.001$) and xanthine ($r = 0.299$,
248 $p < 0.001$). In the CSF, PMI was positively associated with N-acetylglutamate ($r = 0.256$, $p <$
249 0.001) and negatively associated with LysoPE 22:5 ($r = -0.276$, $p < 0.001$, Supplementary Fig
250 1).

251 **Discussion**

252 The results of this study show that there are changes in the metabolite profiles of post-
253 mortem human frontal cortex and CSF that are associated with exposure to tobacco or
254 nicotine products, as assessed by high levels of the nicotine metabolite cotinine in the
255 samples. Furthermore, most of the observed differences were similar in both sexes, with a
256 few exceptions, such as low ergothioneine levels observed especially in the female cases.

257 As expected by study design, the tobacco or nicotine exposure-related metabolites were
258 significantly higher in the cases when compared to the controls. Previous studies have
259 shown that cotinine, a primary metabolite of nicotine, influences the neurotransmitters in
260 the frontal cortex and cerebrospinal fluid²³. For example, cotinine is effective in the
261 activation of the left prefrontal cortex in people who have quit smoking by enhancing the
262 release of neurotransmitters like dopamine and serotonin, while smokers have reduced
263 activation, which has been linked to differing effects on cognitive processing due to
264 nicotine dependence²⁴. However, levels of most neurotransmitters degrade with PMI,
265 which can interfere with the interpretation of results from human post-mortem samples²⁵.
266 Glutamate and acetylcholine are generally more stable than serotonin and dopamine, but
267 they can still undergo changes depending on the PMI and storage conditions²⁵.

268 Furthermore, we observed low levels of taurine in the frontal cortex of the cases when
269 compared to the controls, in line with a previous report of decreased levels of taurine in
270 the brain samples of nicotine-exposed mice²⁶. In the brain, taurine plays a role in

271 antioxidative function, similar to the microbiota-associated metabolite ergothioneine,
272 which also showed a trend of low levels in the cotinine-positive group in the present
273 study^{27,28}. In line with our results, low levels of ergothioneine have also been reported in
274 pregnant women who smoke¹⁷. These results suggest increased oxidative stress and
275 reduced antioxidative capacity in smoking- or nicotine-exposed brains.

276 Moreover, the cases had high levels of N-acetylputrescine in the frontal cortex samples
277 when compared to the controls. High N-acetylputrescine levels have been linked to, for
278 example, Parkinson's disease, glioblastoma and neurodevelopmental problems²⁹⁻³². High
279 N-acetylputrescine levels could also be a marker of increased protein breakdown³³.

280 However, this does not seem to be the case here, since another proteolysis marker, 3-
281 methylhistidine, was significantly lower in the cases, and the average PMI was also lower in
282 the cases compared to controls. Therefore, more prolonged bodily degradation does not
283 explain the group difference of N-acetylputrescine.

284 Additionally, we observed high 1-methylhistamine (a brain-derived metabolite of histamine)
285 levels in the frontal cortex samples from the cases. Previously, high 1-methylhistamine
286 levels have been reported in young adults with a history of high alcohol use, where high 1-
287 methylhistamine levels were associated with low brain gray matter volume³⁴. High 1-
288 methylhistamine levels have been proposed to be associated with elevated histamine
289 levels and inflammatory processes in the brain³⁵.

290 Furthermore, the cases had low levels of aspartic acid in the frontal cortex compared to the
291 controls. In the brain, aspartic acid binds to NMDA receptors and is associated with

292 neuroplasticity³⁶. There were trends towards lower levels of other neurotransmitters,
293 namely glutamate and acetylcholine, in the frontal cortex samples of the cases. Overall, this
294 suggests that the cases have altered neurochemistry compared to controls. This is
295 consistent with repeated chronic exposure to nicotine, which increases levels of nAChRs
296 and likely leads to a reduction in acetylcholine levels in the brain^{7,37,38}. Low levels of these
297 neurotransmitters in the frontal cortex could indicate altered neuroplasticity and activity in
298 the cases. Additionally, a previous study has reported that with nicotine exposure,
299 acetylcholine levels were elevated in the striatum, and glutamate levels were reduced in
300 the hippocampus and striatum, but increased in the nucleus accumbens and prefrontal
301 cortex in mice²⁶. In humans, increased circulating levels of glutamate have been reported in
302 smokers^{14,16}. However, here we did not see an increase in CSF glutamate levels, and the
303 glutamate and acetylcholine levels were decreased in the frontal cortex. These results
304 indicate that the frontal cortex metabolome is, to some degree, independent of the levels
305 of these metabolites in the blood.

306 Moreover, we observed trends of decreased levels of several B-vitamins in cases compared
307 to controls in the frontal cortex. Previously, low blood pantothenic acid (B5) is linked to
308 smoking¹³. These alterations could be due to diet, a notion which is supported by the
309 trends of decreased levels of other metabolites associated with diet like proline betaine
310 and theobromine, seen in the cases.

311 Limitations of the study include factors like smoking status not being available for all
312 subjects. Additionally, some high cotinine levels could be due to nicotine from other

313 sources, such as snuff or nicotine replacement therapy. Electronic cigarettes, nicotine
314 pouches, or similar products containing high levels of nicotine without tobacco for
315 recreational use were not common in Finland during the period of sample collection (2010–
316 2015). Therefore, it is presumed that most of the nicotine exposure leading to high cotinine
317 levels in this cohort is due to exposure to tobacco. Furthermore, these results are from a
318 single cohort with a relatively small number of subjects and therefore they should be
319 validated in a larger study with subjects from more diverse backgrounds. Even though
320 there were no significant differences between cases and controls in PMI, some of the
321 results could be influenced by PMI. This is seen in the PMI correlation in the frontal cortex
322 with aspartic acid, asparagine, xanthine, and in the CSF with N-acetylglutamate and LysoPE
323 22:5. These post-mortem effects increase variation between samples, necessitating larger
324 sample sizes to observe exposure-related effects with adequate statistical power. Despite
325 these limitations, post-mortem samples provide a unique opportunity to obtain high-
326 quality metabolomics data from the human brain¹⁹. Future studies should investigate how
327 the brain metabolome is altered in subjects exposed to nicotine-only-containing products.

328 In conclusion, the current study successfully investigated changes in human post-mortem
329 frontal cortex and CSF metabolite profiles associated with tobacco smoking or nicotine
330 exposure. Cases had higher levels of metabolites associated with increased oxidative stress
331 and inflammation in the frontal cortex, and lower levels of neurotransmitters in the frontal
332 cortex. Further studies are needed in several different populations, to broaden the reach of
333 these results.

334 **REFERENCES**

335

- 336 1. Peacock A, Leung J, Larney S, et al. Global statistics on alcohol, tobacco and illicit drug
337 use: 2017 status report. *Addiction*. 2018;113(10):1905-1926. doi:10.1111/add.14234
- 338 2. Herman M, Tarran R. E-cigarettes, nicotine, the lung and the brain: multi-level cascading
339 pathophysiology. *J Physiol*. 2020;598(22):5063-5071. doi:10.1113/JP278388
- 340 3. Hahad O, Kuntic M, Kuntic I, Daiber A, Münzel T. Tobacco smoking and vascular biology
341 and function: evidence from human studies. *Pflugers Arch*. 2023;475(7):797-805.
342 doi:10.1007/s00424-023-02805-z
- 343 4. Shen N, Gong T, Wang JD, et al. Cigarette smoke-induced pulmonary inflammatory
344 responses are mediated by EGR-1/GGPPS/MAPK signaling. *Am J Pathol*. 2011;178(1):110-
345 118. doi:10.1016/j.ajpath.2010.11.016
- 346 5. Tan X, Vrana K, Ding ZM. Cotinine: Pharmacologically Active Metabolite of Nicotine and
347 Neural Mechanisms for Its Actions. *Front Behav Neurosci*. 2021;15:758252.
348 doi:10.3389/fnbeh.2021.758252
- 349 6. Albuquerque EX, Pereira EFR, Alkondon M, Rogers SW. Mammalian nicotinic
350 acetylcholine receptors: from structure to function. *Physiol Rev*. 2009;89(1):73-120.
351 doi:10.1152/physrev.00015.2008
- 352 7. Colyer-Patel K, Kuhns L, Weidema A, Lesscher H, Cousijn J. Age-dependent effects of
353 tobacco smoke and nicotine on cognition and the brain: A systematic review of the
354 human and animal literature comparing adolescents and adults. *Neurosci Biobehav Rev*.
355 2023;146:105038. doi:10.1016/j.neubiorev.2023.105038
- 356 8. Chang RCC, Ho YS, Wong S, Gentleman SM, Ng HK. Neuropathology of cigarette
357 smoking. *Acta Neuropathol*. 2014;127(1):53-69. doi:10.1007/s00401-013-1210-x
- 358 9. Sutherland MT, Riedel MC, Flannery JS, et al. Chronic cigarette smoking is linked with
359 structural alterations in brain regions showing acute nicotinic drug-induced functional
360 modulations. *Behav Brain Funct*. 2016;12(1):16. doi:10.1186/s12993-016-0100-5
- 361 10. Cross SJ, Linker KE, Leslie FM. Sex-dependent effects of nicotine on the developing
362 brain. *J Neurosci Res*. 2017;95(1-2):422-436. doi:10.1002/jnr.23878
- 363 11. Lin F, Han X, Wang Y, et al. Sex-specific effects of cigarette smoking on caudate and
364 amygdala volume and resting-state functional connectivity. *Brain Imaging Behav*.
365 2021;15(1):1-13. doi:10.1007/s11682-019-00227-z

- 366 12. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. *Cold*
367 *Spring Harb Mol Case Stud.* 2015;1(1):a000588. doi:10.1101/mcs.a000588
- 368 13. Gu F, Derkach A, Freedman ND, et al. Cigarette smoking behaviour and blood
369 metabolomics. *Int J Epidemiol.* 2016;45(5):1421-1432. doi:10.1093/ije/dyv330
- 370 14. Harada S, Ohmomo H, Matsumoto M, et al. Metabolomics profiles alterations in
371 cigarette smokers and heated tobacco product users. *J Epidemiol.* Published online
372 November 4, 2023. doi:10.2188/jea.JE20230170
- 373 15. Hsu PC, Lan RS, Brasky TM, et al. Metabolomic profiles of current cigarette smokers.
374 *Mol Carcinog.* 2017;56(2):594-606. doi:10.1002/mc.22519
- 375 16. Xu T, Holzapfel C, Dong X, et al. Effects of smoking and smoking cessation on human
376 serum metabolite profile: results from the KORA cohort study. *BMC Med.* 2013;11:60.
377 doi:10.1186/1741-7015-11-60
- 378 17. Masvosva W, Voutilainen T, Lehtonen M, et al. Alterations in the plasma metabolome
379 associated with maternal smoking during the first trimester. Published online
380 November 29, 2024. doi:10.1101/2024.11.28.24318123
- 381 18. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and
382 therapeutics. *Annu Rev Pharmacol Toxicol.* 2009;49:57-71.
383 doi:10.1146/annurev.pharmtox.48.113006.094742
- 384 19. Kärkkäinen O, Kokla M, Lehtonen M, et al. Changes in the metabolic profile of human
385 male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy
386 alcohol use. *Addict Biol.* 2021;26(6):e13035. doi:10.1111/adb.13035
- 387 20. Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for
388 comprehensive metabolome analysis. *Nat Methods.* 2015;12(6):523-526.
389 doi:10.1038/nmeth.3393
- 390 21. Klåvus A, Kokla M, Noerman S, et al. "notame": Workflow for Non-Targeted LC-MS
391 Metabolic Profiling. *Metabolites.* 2020;10(4):135. doi:10.3390/metabo10040135
- 392 22. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for
393 chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards
394 Initiative (MSI). *Metabolomics.* 2007;3(3):211-221. doi:10.1007/s11306-007-0082-2
- 395 23. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A. Effect of nicotine on extracellular levels of
396 neurotransmitters assessed by microdialysis in various brain regions: role of glutamic
397 acid. *Neurochem Res.* 1992;17(3):265-271. doi:10.1007/BF00966669

- 398 24. Ernst M, Matochik JA, Heishman SJ, et al. Effect of nicotine on brain activation during
399 performance of a working memory task. *Proc Natl Acad Sci U S A*. 2001;98(8):4728-4733.
400 doi:10.1073/pnas.061369098
- 401 25. Furczyk K, Schutová B, Michel TM, Thome J, Büttner A. The neurobiology of suicide - A
402 Review of post-mortem studies. *J Mol Psychiatry*. 2013;1(1):2. doi:10.1186/2049-9256-1-2
- 403 26. Li H, Chen B, Shao X, et al. 1H-Nuclear magnetic resonance-based metabolomic analysis
404 of brain in mice with nicotine treatment. *BMC Neurosci*. 2014;15:32. doi:10.1186/1471-
405 2202-15-32
- 406 27. Ahmed H, Leyrolle Q, Koistinen V, et al. Microbiota-derived metabolites as drivers of
407 gut-brain communication. *Gut Microbes*. 2022;14(1):2102878.
408 doi:10.1080/19490976.2022.2102878
- 409 28. Sener G, Ozer Sehirli A, Ipçi Y, et al. Taurine treatment protects against chronic nicotine-
410 induced oxidative changes. *Fundam Clin Pharmacol*. 2005;19(2):155-164.
411 doi:10.1111/j.1472-8206.2005.00322.x
- 412 29. Jiang Z, Wang X, Zhang H, et al. Ketogenic diet protects MPTP-induced mouse model of
413 Parkinson's disease via altering gut microbiota and metabolites. *MedComm (2020)*.
414 2023;4(3):e268. doi:10.1002/mco2.268
- 415 30. Rodan LH, Anyane-Yeboah K, Chong K, et al. Gain-of-function variants in the ODC1 gene
416 cause a syndromic neurodevelopmental disorder associated with macrocephaly,
417 alopecia, dysmorphic features, and neuroimaging abnormalities. *Am J Med Genet A*.
418 2018;176(12):2554-2560. doi:10.1002/ajmg.a.60677
- 419 31. Saiki S, Sasazawa Y, Fujimaki M, et al. A metabolic profile of polyamines in parkinson
420 disease: A promising biomarker. *Ann Neurol*. 2019;86(2):251-263. doi:10.1002/ana.25516
- 421 32. Wang DH, Fujita Y, Dono A, et al. The genomic alterations in glioblastoma influence the
422 levels of CSF metabolites. *Acta Neuropathol Commun*. 2024;12(1):13.
423 doi:10.1186/s40478-024-01722-1
- 424 33. Liu R, Li P, Bi CW, et al. Plasma N-acetylputrescine, cadaverine and 1,3-diaminopropane:
425 potential biomarkers of lung cancer used to evaluate the efficacy of anticancer drugs.
426 *Oncotarget*. 2017;8(51):88575-88585. doi:10.18632/oncotarget.19304
- 427 34. Heikkinen N, Kärkkäinen O, Laukkanen E, et al. Changes in the serum metabolite profile
428 correlate with decreased brain gray matter volume in moderate-to-heavy drinking
429 young adults. *Alcohol*. 2019;75:89-97. doi:10.1016/j.alcohol.2018.05.010
- 430 35. Carthy E, Ellender T. Histamine, Neuroinflammation and Neurodevelopment: A Review.
431 *Front Neurosci*. 2021;15:680214. doi:10.3389/fnins.2021.680214

- 432 36. Jewett BE, Thapa B. Physiology, NMDA Receptor. In: *StatPearls*. StatPearls Publishing;
433 2024. Accessed November 14, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK519495/>
- 434 37. Moretti M, Mugnaini M, Tessari M, et al. A comparative study of the effects of the
435 intravenous self-administration or subcutaneous minipump infusion of nicotine on the
436 expression of brain neuronal nicotinic receptor subtypes. *Mol Pharmacol*.
437 2010;78(2):287-296. doi:10.1124/mol.110.064071
- 438 38. Smart K, Naganawa M, Baldassarri SR, et al. PET Imaging Estimates of Regional
439 Acetylcholine Concentration Variation in Living Human Brain. *Cereb Cortex*.
440 2021;31(6):2787-2798. doi:10.1093/cercor/bhaa387

441

442